Mogrify Limited, a regenerative medicine company, appoints Dr. Jonathan Appleby as Chief Scientific Officer, bringing decades of industry experience in therapeutic development. Dr. Appleby previously worked at the Cell and Gene Therapy Catapult and GSK, leading the development of innovative therapies like StrimvelisTM and ARSA gene therapy. His role will involve advancing Mogrify’s therapeutic programs in otology, ophthalmology, and diabetes towards clinical development. CEO Dr. Darrin M. Disley welcomes Dr. Appleby, highlighting his expertise in developing medicines for patients with limited treatment options. Dr. Appleby expresses excitement in joining Mogrify’s team and utilizing their proprietary platform to address various diseases with novel therapies.
Source link
Mogrify appoints Dr. Jonathan Appleby as Chief Scientific Officer
